Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Compact Benchtop System Enables Preparative Protein Purification in any Laboratory

By BiotechDaily International staff writers
Posted on 03 Dec 2013
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
A compact preparative chromatography instrument that is compatible with prepacked or user prepared columns and can be combined with fraction collectors to generate a complete protein purification system in any biotech or life sciences laboratory is now on the market.

The GE Healthcare (Chalfont St. Giles, United Kingdom) ÄKTA start is designed as a stand-alone system that combines a front-facing flow path with a user-friendly interface. The system is controlled via an intuitive touchscreen, which displays the UV curve and other run data in real-time.

ÄKTA start is compatible with all common purification techniques, including affinity and ion exchange chromatography, desalting, buffer exchange, and gel filtration. The system supports purification of tagged proteins, antibodies, untagged or native proteins, and sample clean-up applications. ÄKTA start can be operated using predefined quick-start protocols, built-in templates, or by creating custom protocols. Prepacked columns are available for common applications.

The ÄKTA start instrument can be augmented with GE Healthcare's Frac30 fraction collector for automatic protein collection, and with user-friendly UNICORN start 1.0 control software, which provides additional evaluation tools and the ability to control ÄKTA start from a computer.

Related Links:

GE Healthcare



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.